Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
This study was to compare the clinical characteristics and prognosis of Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL) and lymph node DLBCL (LN-DLBCL) in the rituximab era. Before propensity score-matched (PSM), WR-DLBCL group shows more favorable clinical characteristics than LN-DLBCL group. After PSM, there was no significant difference in the response rate and survivals between them. The 5-year PFS and OS rates were 65.0% and 78.6% for WR-DLBCL group, respectively, and 53.7% and 66.1% for LN-DLBCL group, respectively. In WR-DLBCL group, ECOG score, Ann Arbor stage, B symptoms and IPI were associated with poor PFS and OS. In LN-DLBCL group, ECOG score, Ann Arbor stage, LDH, and IPI were significant factors to PFS and OS. Multivariate analysis showed that Ann Arbor stage was the only significant factor to PFS for WR-DLBCL group, for LN-DLBCL group, Ann Arbor stage and IPI were independent factors to PFS, LDH was the only significant factor to OS. WR-DLBCL was associated with more favorable clinical characteristics compared with LN-DLBCL, whereas, WR involvement itself did not have a real favorable prognostic significance. The PFS and OS of DLBCL were largely dependent on other prognostic factors such as Ann Arbor stage, LDH or IPI.
['Jing|Xiao-Mei|XM|', 'Yu|Jing-Rui|JR|', 'Luo|Yang-Kun|YK|', 'Zhang|Shi-Chuan|SC|', 'Liu|Ji-Feng|JF|', 'Li|Li|L|', 'Wu|Ping|P|', 'Zhang|Zhi-Hui|ZH|']
D018572:Disease-Free Survival D005260:Female D006801:Humans D008198:Lymph Nodes D016403:Lymphoma, Large B-Cell, Diffuse D008297:Male D008875:Middle Aged D000069283:Rituximab D015996:Survival Rate
Prognosis Lymph node Diffuse large B-cell lymphoma Rituximab Waldeyer’s ring